Market Cap (In USD)
589.61 Million
Revenue (In USD)
-
Net Income (In USD)
-98.14 Million
Avg. Volume
328.77 Thousand
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 12.58-33.92
- PE
- -
- EPS
- -
- Beta Value
- 0.0
- ISIN
- US14179K1016
- CUSIP
- 14179K101
- CIK
- 1966494
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Ms. Gina Chapman
- Employee Count
- -
- Website
- https://cargo-tx.com
- Ipo Date
- 2023-11-13
- Details
- CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.
More Stocks
-
HXLHexima Limited
HXL
-
SESNSesen Bio, Inc.
SESN
-
ATMCW
-
LVVV
-
ALQWAQwamplify
ALQWA
-
300102Xiamen Changelight Co., Ltd.
300102
-
PTOSP2 Solar, Inc
PTOS
-
CRVOCervoMed Inc.
CRVO